ArticleJournal of cellular and molecular medicine2025
Integrative Disulfidptosis-Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The emerging role of disulfidptosis in metabolic synergistic death and cancer immunotherapy.Oncogenesis · 2026Review
- RPN1 at the crossroads of glycosylation, tumor immunity, and disulfidptosis.Frontiers in pharmacology · 2026Review
- Disulfidptosis: A Metabolic Cell Death Mechanism with Therapeutic Potential in Cancer.Oncology research · 2026Review
- The functional and clinical significance of nucleoporin NUP153 across human cancers: a systematic study based on multi-omics analysis and bench work validation.Frontiers in immunology · 2025Article
- METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery.Frontiers in immunology · 2025Article
- Immune Dysregulation and Prognosis in Sepsis: Insights From a Posttranslational Perspective.Human mutation · 2025Article
- Single-cell and spatial atlas of glioblastoma heterogeneity: characterizing theFrontiers in immunology · 2025Article
- Single-cell atlas of endothelial cells in atherosclerosis: identifying C1 CXCL12+ ECs as key proliferative drivers for immunological precision therapeutics in atherosclerosis.Frontiers in immunology · 2025Article
- The role of ATF3 in precision medicine of brain arteriovenous malformation: based on endothelial cell proliferation.Frontiers in immunology · 2025Article
- Epithelial cells with high TOP2A expression promote cervical cancer progression by regulating the transcription factor FOXM1.Frontiers in oncology · 2025Article
- ScRNA-seq combined with ATAC-seq analysis to explore the metabolic balance mechanism of CCl4-induced liver inflammatory injury.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disulfidptosis, a new form of programmed cell death, plays a role in multiple types of cancer. However, research on disulfidptosis in glioma is lacking. A disulfidptosis-associated risk score was constructed using Cox regression modelling, while LASSO regression was applied for feature selection. To explore the relationship between the risk score and the immune microenvironment, we employed CIBERSORT, ssGSEA and ESTIMATE algorithms. Additionally, wet lab experiments were conducted to validate the functional role of the key disulfidptosis gene RPN1, demonstrating its ability to promote glioma cell proliferation and migration. Disulfidptosis genes were significantly upregulated in gliomas, influencing clinical features and survival. The risk score effectively predicted OS and varied among clinical subgroups. High-risk scores correlated with tumour growth, invasion and immunosuppression. Patients with different risk scores showed distinct immune cell infiltration patterns. Most immune checkpoints and chemokines were positively associated with risk scores. Laboratory findings confirmed that RPN1 significantly promoted glioma cell proliferation and migration. Disulfidptosis-based risk assessment stratifies glioma prognosis and reveals immune microenvironment characteristics, offering insights for personalised treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.